... risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics. 2003;72(5):1117-1130 [213] King MC ...
... ovarian cancer: Causality, clinical implica- tions, and “targeted prevention”. Clinical Obstetrics and Gynecology 55 (1):24–35. doi:10.1097/ GRF.0b013e31824b1725. Cruz C, Teule A, Caminal JM, Blanco I, Piulats JM ... Breast Cancer 183.
... growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers . Breast Cancer Res . 2009 , 11 , R76 . 31. Slattery , M.L .; Samowitz , W .; Curtin , K .; Ma , K.N .; Hoffman , M .; Caan , B .; Neuhausen , S.
... nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol. Biomark. Prev. 2012, 21, 1362–1370. [CrossRef] 79. Kuchenbaecker, K.B. ...
... cancer risk . Breast Cancer Res 2009 ; 11 ( Suppl . 3 ) : S3 . PMID : 20030878 . [ 26 ] Hamajima N , Hirose K ... BRCA1 and BRCA2 among Ashkenazi Jews . N Engl J Med 1997 ; 336 ( 20 ) : 1401–8 . [ 39 ] Couch FJ , Nathanson KL ...
Introducing the definitive gynecologic oncology reference and surgical atlas—in one essential text Gynecologic Oncology: Clinical Practice and Surgical Atlas brings together a skill-sharpening reference and full-color atlas to deliver an ...
This book offers a broad-ranging assessment of current efforts of the molecular, cellular, hormonal, nutritional and lifestyle strategies being tested and applied by biogerontologists in the search for effective means of intervention, ...
This coverage will enable medical oncologists and students as well as basic researchers to capture the up-to-date entire picture of human telomeres and telomerase in cancer.
This text includes sections on anatomy, normal and abnormal physiology, investigation techniques, inflammatory conditions and treatment options.
This book was written to summarize the midterm meeting of the concerted action BMH4-CT98-3085 funded by the European Union in the context of the BIOMEDII programme.